MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling
Braz. j. med. biol. res
;
54(9): e10390, 2021. graf
Article
Dans Anglais
| LILACS
| ID: biblio-1249337
ABSTRACT
Sorafenib (SOR) resistance is still a significant challenge for the effective treatment of hepatocellular carcinoma (HCC). The mechanism of sorafenib resistance remains unclear. Several microRNAs (miRNAs) have been identified as playing a role in impairing the sensitivity of tumor cells to treatment. We examined the mechanism behind the role of miR-92b in mediating sorafenib resistance in HCC cells. We detected that miR-92b expression was significantly upregulated in SOR-resistant HepG2/SOR cells compared to parental HepG2/WT cells. After transfection with miR-92b inhibitor, the proliferation of HepG2/SOR cells was remarkably weakened and rates of apoptosis significantly increased. PTEN was considered to be a functional target of miR-92b according to a luciferase reporter assay. Knockdown of PTEN significantly impaired the ability of miR-92b inhibitor on increasing sorafenib sensitivity of HepG2/SOR cells. Furthermore, we confirmed by western blotting and immunofluorescence that miR-92b can mediate sorafenib resistance by activating the PI3K/AKT/mTOR pathway in HCC cells by directly targeting PTEN. These findings further validate the mechanism of miR-92b in SOR resistance in HCC treatment.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Carcinome hépatocellulaire
/
Résistance aux médicaments antinéoplasiques
/
MicroARN
/
Sorafénib
/
Tumeurs du foie
Type d'étude:
Étude pronostique
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Braz. j. med. biol. res
Thème du journal:
Biologie
/
Médicament
Année:
2021
Type:
Article
Pays d'affiliation:
Chine
Institution/Pays d'affiliation:
Affiliated Hospital of Nantong University/CN
/
The First Affiliated Hospital of Soochow University/CN
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS